MRSN logo

Mersana Therapeutics (MRSN) Cash From Operations

Annual CFO

-$168.88 M
-$119.52 M-242.12%

December 31, 2023

Summary

Performance

1-Year Change

-242.12%

3-Year Change

-126.09%

5-Year Change

-205.86%

15-Year Change

-295.7%

MRSN Cash From Operations Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

6.44%
MRSN annual cash flow from operations is higher than 6.44% of companies in Healthcare sector

High & Low

All-time High

$31.59 M
MRSN annual cash flow from operations is currently -634.64% below its historical high of $31.59 million

3-Year Low

-$168.88 M
MRSN annual cash flow from operations is currently at its 3-year low

Earnings dates

Last Annual Earnings Report Date

Dec 31, 2023
MRSN previous annual earnings announcement was published on Dec 31, 2023

Next Annual Earnings Report Date

Feb 28, 2025
MRSN next annual earnings announcement is scheduled for Feb 28, 2025

OtherMRSNcash flowmetrics:

Annual CFI

$119.88 M
MRSN annual cash flow from investing activities is $119.88 million

Annual CFF

$94.67 M
MRSN annual cash flow from financing activities is $94.67 million

Annual FCF

-$171.05 M
MRSN annual free cash flow is -$171.05 million

Annual CAPEX

$2.17 M
MRSN annual capital expenditures is $2.17 million

Quarterly CFO

-$8.58 M
+$13.28 M+60.75%

September 30, 2024

Summary

Performance

3-Month Change

0%

1-Year Change

+81.39%

3-Year Change

+81.39%

5-Year Change

+81.39%

MRSN Quarterly CFO Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

34.7%
MRSN quarterly cash flow from operations is higher than 34.7% of companies in Healthcare sector

High & Low

All-time High

$54.60 M
MRSN quarterly cash flow from operations is currently -115.71% below its historical high of $54.60 million

3-Year Low

-$61.83 M

Earnings dates

Last Quarterly Earnings Report Date

Sep 30, 2024
MRSN previous earnings announcement was published on Sep 30, 2024

Next Quarterly Earnings Report Date

Feb 28, 2025
MRSN next earnings announcement is scheduled for Feb 28, 2025

OtherMRSNcash flowmetrics:

Quarterly CFI

$28.47 M
MRSN quarterly cash flow from investing activities is $28.47 million

Quarterly CFF

-$23.00 K
MRSN quarterly cash flow from financing activities is -$23.00 thousand

Quarterly FCF

-$8.58 M
MRSN quarterly free cash flow is -$8.58 million

Quarterly CAPEX

$0.00
MRSN quarterly capital expenditures is $0.00

TTM CFO

-$95.05 M
+$37.50 M+28.29%

September 30, 2024

Summary

Performance

3-Month Change

0%

1-Year Change

+49.48%

3-Year Change

+49.48%

5-Year Change

+49.48%

MRSN TTM CFO Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

16.28%
MRSN TTM cash flow from operations is higher than 16.28% of companies in Healthcare sector

High & Low

All-time High

$32.07 M
MRSN TTM cash flow from operations is currently -396.38% below its historical high of $32.07 million

3-Year Low

-$188.15 M

Earnings dates

Last Quarterly Earnings Report Date

Sep 30, 2024
MRSN previous earnings announcement was published on Sep 30, 2024

Next Quarterly Earnings Report Date

Feb 28, 2025
MRSN next earnings announcement is scheduled for Feb 28, 2025

OtherMRSNcash flowmetrics:

TTM CFI

-$18.41 M
MRSN TTM cash flow from investing activities is -$18.41 million

TTM CFF

$6.05 M
MRSN TTM cash flow from financing activities is $6.05 million

TTM FCF

-$95.57 M
MRSN TTM free cash flow is -$95.57 million

TTM CAPEX

$518.00 K
MRSN TTM capital expenditures is $518.00 thousand

Cash From Operations Formula

CFO = Net Income + Non Cash Expenses + Changes In Working Capital

MRSN Cash From Operations Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year-242.1%+81.4%+49.5%
3 y3 years-126.1%+81.4%+49.5%
5 y5 years-205.9%+81.4%+49.5%

MRSN Cash From Operations Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year-242.1%at low-115.7%+86.1%-134.5%+49.5%
5 y5-year-242.1%at low-115.7%+86.1%-134.5%+49.5%
alltimeall time-634.6%at low-115.7%+86.1%-396.4%+49.5%

Mersana Therapeutics Cash From Operations History

DateAnnualQuarterlyTTM
Sep 2024
-
-$8.58 M(-60.8%)
-$95.05 M(-28.3%)
Jun 2024
-
-$21.86 M(-33.1%)
-$132.56 M(-23.2%)
Mar 2024
-
-$32.66 M(+2.2%)
-$172.53 M(+2.2%)
Dec 2023
-$168.88 M(+242.1%)
-$31.96 M(-30.6%)
-$168.88 M(-10.2%)
Sep 2023
-
-$46.08 M(-25.5%)
-$188.15 M(+115.1%)
Jun 2023
-
-$61.83 M(+113.2%)
-$87.47 M(+24.2%)
Mar 2023
-
-$29.00 M(-43.4%)
-$70.41 M(+42.6%)
Dec 2022
-$49.36 M(-64.7%)
-$51.23 M(-193.8%)
-$49.36 M(+21.8%)
Sep 2022
-
$54.60 M(-221.9%)
-$40.53 M(-69.1%)
Jun 2022
-
-$44.78 M(+462.9%)
-$131.23 M(+8.5%)
Mar 2022
-
-$7.96 M(-81.2%)
-$120.92 M(-13.6%)
Dec 2021
-$139.99 M(+87.4%)
-$42.40 M(+17.5%)
-$139.99 M(+21.8%)
Sep 2021
-
-$36.10 M(+4.7%)
-$114.91 M(+16.1%)
Jun 2021
-
-$34.47 M(+27.6%)
-$99.00 M(+23.0%)
Mar 2021
-
-$27.02 M(+56.0%)
-$80.47 M(+7.7%)
Dec 2020
-$74.70 M
-$17.32 M(-14.2%)
-$74.70 M(+6.8%)
Sep 2020
-
-$20.20 M(+26.7%)
-$69.95 M(+5.9%)
Jun 2020
-
-$15.94 M(-25.0%)
-$66.04 M(+2.7%)
DateAnnualQuarterlyTTM
Mar 2020
-
-$21.25 M(+68.9%)
-$64.30 M(-5.1%)
Dec 2019
-$67.74 M(+22.7%)
-$12.58 M(-22.8%)
-$67.74 M(-4.7%)
Sep 2019
-
-$16.28 M(+14.7%)
-$71.07 M(+8.9%)
Jun 2019
-
-$14.20 M(-42.5%)
-$65.26 M(+4.4%)
Mar 2019
-
-$24.69 M(+55.2%)
-$62.51 M(+13.2%)
Dec 2018
-$55.22 M(+29.4%)
-$15.90 M(+51.8%)
-$55.22 M(+9.8%)
Sep 2018
-
-$10.47 M(-8.5%)
-$50.31 M(-1.2%)
Jun 2018
-
-$11.45 M(-34.2%)
-$50.92 M(+3.6%)
Mar 2018
-
-$17.39 M(+58.1%)
-$49.16 M(+15.2%)
Dec 2017
-$42.68 M(-235.1%)
-$11.00 M(-0.8%)
-$42.68 M(+130.6%)
Sep 2017
-
-$11.08 M(+14.4%)
-$18.51 M(+51.7%)
Jun 2017
-
-$9.69 M(-11.2%)
-$12.20 M(+7.1%)
Mar 2017
-
-$10.91 M(-182.8%)
-$11.39 M(-136.1%)
Dec 2016
$31.59 M(-427.8%)
$13.18 M(-375.9%)
$31.59 M(+71.6%)
Sep 2016
-
-$4.78 M(-46.2%)
$18.41 M(-20.6%)
Jun 2016
-
-$8.88 M(-127.7%)
$23.19 M(-27.7%)
Mar 2016
-
$32.07 M
$32.07 M
Dec 2015
-$9.64 M
-
-

FAQ

  • What is Mersana Therapeutics annual cash flow from operations?
  • What is the all time high annual CFO for Mersana Therapeutics?
  • What is Mersana Therapeutics annual CFO year-on-year change?
  • What is Mersana Therapeutics quarterly cash flow from operations?
  • What is the all time high quarterly CFO for Mersana Therapeutics?
  • What is Mersana Therapeutics quarterly CFO year-on-year change?
  • What is Mersana Therapeutics TTM cash flow from operations?
  • What is the all time high TTM CFO for Mersana Therapeutics?
  • What is Mersana Therapeutics TTM CFO year-on-year change?

What is Mersana Therapeutics annual cash flow from operations?

The current annual CFO of MRSN is -$168.88 M

What is the all time high annual CFO for Mersana Therapeutics?

Mersana Therapeutics all-time high annual cash flow from operations is $31.59 M

What is Mersana Therapeutics annual CFO year-on-year change?

Over the past year, MRSN annual cash flow from operations has changed by -$119.52 M (-242.12%)

What is Mersana Therapeutics quarterly cash flow from operations?

The current quarterly CFO of MRSN is -$8.58 M

What is the all time high quarterly CFO for Mersana Therapeutics?

Mersana Therapeutics all-time high quarterly cash flow from operations is $54.60 M

What is Mersana Therapeutics quarterly CFO year-on-year change?

Over the past year, MRSN quarterly cash flow from operations has changed by +$37.50 M (+81.39%)

What is Mersana Therapeutics TTM cash flow from operations?

The current TTM CFO of MRSN is -$95.05 M

What is the all time high TTM CFO for Mersana Therapeutics?

Mersana Therapeutics all-time high TTM cash flow from operations is $32.07 M

What is Mersana Therapeutics TTM CFO year-on-year change?

Over the past year, MRSN TTM cash flow from operations has changed by +$93.10 M (+49.48%)